Inoculation of the Leishmania infantum HSP70-II Null Mutant Induces Long-Term Protection against L. amazonensis Infection in BALB/c Mice
<i>Leishmania amazonensis</i> parasites are etiological agents of cutaneous leishmaniasis in the New World. BALB/c mice are highly susceptible to <i>L. amazonensis</i> challenge due to their inability to mount parasite-dependent IFN-γ-mediated responses. Here, we analyzed the...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/230993 |
| Acceso en línea: | http://hdl.handle.net/10261/230993 |
| Access Level: | acceso abierto |
| Palabra clave: | Leishmania amazonensis Live vaccines Attenuated parasites Murine leishmaniasis BALB/c mice IFN-y |
| Sumario: | <i>Leishmania amazonensis</i> parasites are etiological agents of cutaneous leishmaniasis in the New World. BALB/c mice are highly susceptible to <i>L. amazonensis</i> challenge due to their inability to mount parasite-dependent IFN-γ-mediated responses. Here, we analyzed the capacity of a single administration of the <i>LiΔHSP70-II</i> genetically-modified attenuated <i>L. infantum</i> line in preventing cutaneous leishmaniasis in mice challenged with <i>L. amazonensis</i> virulent parasites. In previous studies, this live attenuated vaccine has demonstrated to induce long-protection against murine leishmaniasis due to Old World <i>Leishmania</i> species. Vaccinated mice showed a reduction in the disease evolution due to <i>L. amazonensis</i> challenge, namely reduction in cutaneous lesions and parasite burdens. In contrast to control animals, after the challenge, protected mice showed anti-<i>Leishmania</i> IgG2a circulating antibodies accompanied to the induction of <i>Leishmania</i>-driven specific IFN-γ systemic response. An analysis performed in the lymph node draining the site of infection revealed an increase of the parasite-specific IFN-ϒ production by CD4<sup>+</sup> and CD8<sup>+</sup> T cells and a decrease in the secretion of IL-10 against leishmanial antigens. Since the immunity caused by the inoculation of this live vaccine generates protection against different forms of murine leishmaniasis, we postulate <i>LiΔHSP70-II</i> as a candidate for the development of human vaccines. |
|---|